Royalty Pharma (RPRX) Shares Outstanding (Weighted Average) (2020 - 2026)

Royalty Pharma has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $436.8 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $436.8 million, changed 0.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $436.8 million (changed 0.3% YoY), and the FY2025 annual result was $429.8 million, down 4.1% from the prior year.
• Shares Outstanding (Weighted Average) came in at $436.8 million for Q1 2026 at Royalty Pharma, up from $429.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $451.0 million in Q2 2024 to a low of $423.5 million in Q2 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $438.0 million (2022), against an average of $440.4 million.
• Across the five-year window, Shares Outstanding (Weighted Average) climbed 11.34% in 2022 and slipped 6.1% in 2025, its largest moves.
• Royalty Pharma's Shares Outstanding (Weighted Average) stood at $438.0 million in 2022, then rose by 2.2% to $447.6 million in 2023, then climbed by 0.13% to $448.2 million in 2024, then dropped by 4.1% to $429.8 million in 2025, then gained by 1.63% to $436.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $436.8 million (Q1 2026), $429.8 million (Q4 2025), and $430.3 million (Q3 2025), per Business Quant data.